Gene therapy of metachromatic leukodystrophy

Bibliography

• GUSTAVSON KH, HAGBERG B: The incidence and genetics of metachromatic leucodystrophy in northern Sweden. Acta Paediatr. Scand. (1971) 60(5):585–590.
   PubMed Web of Science ®Google Scholar
• HEIM P, CLAUSSEN M, HOFFMANN B et al.: Leukodystrophy incidence in Germany. Am. J. Med. Genet. (1997) 71(4):475–478.
   PubMed Web of Science ®Google Scholar
• VON FIGURA K, GIESELMANN V, JAEKEN J: Metachromatic leukodystrophy. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (Eds), McGraw-Hill, New York, USA (2000:3695–3724.
   Google Scholar
• ••A comprehensive review summarising thegenetics and pathology of MLD, the biochemistry of ASA, and therapy approaches in ASA knockout mice.
   Google Scholar
• SANDHOFF K, KOLTER T, HARZER K: Sphingolipid activator proteins. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (Eds), McGraw-Hill, New York, USA (2000:3371–3388.
   Google Scholar
• ISHIBASHI T, DUPREE JL, IKENAKA K et al.: A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation. J. Neurosci. (2002) 22(15):6507–6514.
   PubMed Web of Science ®Google Scholar
• HIRAHARA Y, BANSAL R, HONKE K et al.: Sulfatide is a negative regulator of oligodendrocyte differentiation: development in sulfatide-null mice. Glia (2004) 45(3):269–277.
   PubMed Web of Science ®Google Scholar
• HESS B, SAFTIG P, HARTMANN D et aL: Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc. Nail. Acad. Sc.. USA (1996) 93(25):14821–14826.
   PubMed Web of Science ®Google Scholar
• ••Describes the construction of the ASAknockout mouse model for MLD.
   Google Scholar
• GIESELMANN V FRANKEN S, KLEIN D et al.: Metachromatic leukodystrophy: consequences of sulphatide accumulation. Acta Paediatr. SuppL (2003) 92(443):74–79.
   PubMedGoogle Scholar
• •A recent review on the phenotype and molecular pathology of ASA knockout mice.
   Google Scholar
• SCHOTT I, HARTMANN D, GIESELMANN V, LULLMANN-RAUCH R: Sulfatide storage in visceral organs of arylsulfatase A-deficient mice. Virchows Arch. (2001) 439(1):90–96.
   PubMed Web of Science ®Google Scholar
• WITTKE D, HARTMANN D, GIESELMANN V, LULLMANN-RAUCH R: Lysosomal sulfatide storage in the brain of arylsulfatase A-deficient mice: cellular alterations and topographic distribution. Acta NeuropathoL (Berl.) (2004) 108(4):261–271.
   PubMed Web of Science ®Google Scholar
• D'HOOGE R, COENEN R, GIESELMANN V, LULLMANN-RAUCH R, DE DEYN PP: Decline in brainstem auditory-evoked potentials coincides with loss of spiral ganglion cells in arylsulfatase A-deficient mice. Brain Res. (1999) 847(2):352–356.
   PubMed Web of Science ®Google Scholar
• CONSIGLIO A. QUATTRINI A. MARTINO S et al.: In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. (2001) 7(3):310–316.
   Google Scholar
• ••Describes the high therapeutic potential oflentivirally mediated in vivo gene therapy.
   Google Scholar
• D'HOOGE R, HARTMANN D, MANIL J, COLIN F, GIESELMANN DE DEYN PP: Neuromotor alterations and cerebellar deficits in aged arylsulfatase A-deficient transgenic mice. Neurosci. Lett. (1999) 273(2):93–96.
   PubMed Web of Science ®Google Scholar
• D'HOOGE R, VAN DAM D, FRANCK F, GIESELMANN V DE DEYN PP: Hyperactivity, neuromotor defects, and impaired learning and memory in a mouse model for metachromatic leukodystrophy. Brain Res. (2001) 907(1-2):35–43.
   PubMed Web of Science ®Google Scholar
• NEUFELD EF, MUENZER J: The mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), Mc Graw-Hill, New York, USA (1989):1565–1587.
   Google Scholar
• STORCH S, BRAULKE T: Transport of lysosomal enzymes. In: Lysosomes. Saftig P (Ed.), Landes Bioscience, Georgetown, TX, USA. (In Press).
   Google Scholar
• •A review describing the M6P-dependent targeting of lysosomal enzymes.
   Google Scholar
• CHAO HH, WAHEED A, POHLMANN R, HILLE A, VON FIGURA K: Mannose 6-phosphate receptor dependent secretion of lysosomal enzymes. EMBO J. (1990) 9(10:3507–3513.
   PubMedGoogle Scholar
• •Demonstrates that a substantial fraction of ASA is delivered from cells.
   Google Scholar
• NEUFELD EF, FRATANTONI JC: Inborn errors of mucopolysaccharide metabolism. Science (1970) 169(941):141–146.
   PubMedGoogle Scholar
• ••Pioneering work that defines cross-correction as the mutual exchange of corrective factors secreted from two different LSD cell types.
   Google Scholar
• KORNFELD S, SLY WS: I-cell disease and pseudo-Hurler polydystrophy: disorders of lysosomal enzyme phosphorylation and localization. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (Eds), McGraw-Hill, New York, USA (200 0:3469-3482.
   Google Scholar
• BARTON NW, FURBISH FS, MURRAY GJ, GARFIELD M, BRADY RO: Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc. Natl. Acad. Sci. USA (1990) 87(5):1913–1916.
   PubMed Web of Science ®Google Scholar
• •The first proof-of-principle for the efficacy of enzyme replacement therapy in a LSD.
   Google Scholar
• BROOKS DA: Alpha-L-iduronidase andenzyme replacement therapy for mucopolysaccharidosis I. Expert Opin. Biol. Ther. (2002) 2(8):967–976.
   PubMed Web of Science ®Google Scholar
• BRADY RO, MURRAY GJ, MOORE DF, SCHIFFMANN R: Enzyme replacement therapy in Fabry disease. J. Inherit. Metab. Dis. (2001) 24\(Suppl. 2):18–24.
   Google Scholar
• AMALFITANO A, BENGUR AR, MORSE RP et al.: Recombinant human acid-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a Phase I/II clinical trial. Genet. Med. (2001) 3:132–138.
   PubMed Web of Science ®Google Scholar
• VAN DEN HOUT JM, KAMPHOVEN JH, WINKEL LP et al.: Long-term intravenous treatment of Pompe disease with recombinant human-glucosidase from milk. Pediatrics (2004) 113:e448–e457.
   Google Scholar
• LEINEKUGEL P, MICHEL S, CONZELMANN E, SANDHOFF K: Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum. Genet. (1992) 88(5):513–523.
   PubMed Web of Science ®Google Scholar
• •Demonstrates that low residual ASA activities are sufficient to prevent MLD.
   Google Scholar
• PENZIEN JM, KAPPLER J, HERSCHKOWITZ N et aL: Compound heterozygosity for metachromatic leukodystrophy and arylsulfatase A pseudodeficiency alleles is not associated with progressive neurological disease. Am. J. Hum. Genet. (1993) 52(3):557–564.
   PubMed Web of Science ®Google Scholar
• •Confirms the data of the previous study.
   Google Scholar
• WALKLEY SU, THRALL MA, DOBRENIS K et al.: Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proc. NatL Acad. Sci. USA (1994) 91(8):2970–2974.
   PubMed Web of Science ®Google Scholar
• •The most successful BMT therapy in an animal model for a LSD so far.
   Google Scholar
• LAWSON LJ, PERRY VH, GORDON S: Turnover of resident microglia in the normal adult mouse brain. Neuroscience (1992) 48(2):405–415.
   PubMed Web of Science ®Google Scholar
• KRALL WJ, CHALLITA PM, PERLMUTTER LS, SKELTON DC, KOHN DB: Cells expressing human glucocerebrosidase from a retroviral vector repopulate macrophages and central nervous system microglia after murine bone marrow transplantation. Blood (1994) 83(9):2737–2748.
   PubMed Web of Science ®Google Scholar
• KENNEDY DW, ABKOWITZ JL: Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood (1997) 90(3):986–993.
   PubMed Web of Science ®Google Scholar
• WALKLEY SU, DOBRENIS K: Bone marrow transplantation for lysosomal diseases. Lancet (1995)345:1382–1383.
   PubMed Web of Science ®Google Scholar
• DOBRENIS K, WENGER DA, WALKLEY SU: Extracellular release of lysosomal glycosidases in cultures of cat microglia. Mo/. Biol. Cell (1994) 5:113a.
   Google Scholar
• BIFFI A, DE PALMA M, QUATTRINI A et al.: Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified haematopoietic stem cells. J. Clin. Invest. (2004) 113(8):1118–1129.
   PubMed Web of Science ®Google Scholar
• ••Describes the therapeutic potential oflentivirally mediated BMSC-GT in a mouse model for MLD.
   Google Scholar
• OHASHI T, WATABE K, SATO Y, SAITO I, BARRANGER JA, ETO Successful transduction of oligodendrocytes and restoration of arylsulfatase A deficiency in metachromatic leukodystrophy fibroblasts using an adenovirus vector. Gene Ther. (1995) 2(7):443–449.
   PubMed Web of Science ®Google Scholar
• OHASHI T, WATABE K, SATO Y et ell.: Gene therapy for metachromatic leukodystrophy. Acta Paediatr. Jpn. (1996) 38(2):193–201.
   Google Scholar
• WEI JF, WEI FS, SAMULSKI RJ, BARRANGER JA: Expression of the human glucocerebrosidase and arylsulfatase A genes in murine and patient primary fibroblasts transduced by an adeno-associated virus vector. Gene Ther. (1994) 1(4):261–268.
   PubMed Web of Science ®Google Scholar
• ROMMERSKIRCH W, FLUHARTY AL, PETERS C, VON FIGURA K, GIESELMANN V: Restoration of arylsulphatase A activity in human-metachromatic-leucodystrophy fibroblasts via retroviral-vector-mediated gene transfer. Biochem. J. (1991) 280(Pt 2):459–461.
   PubMedGoogle Scholar
• OHASHI T, ETO Y, LEARISH R, BARRANGER JA: Correction of enzyme deficiency in metachromatic leukodystrophy fibroblasts by retroviral-mediated transfer of the human arylsulphatase A gene. J. Inherit. Metab. Dis. (1993) 16(5):881–885.
   PubMed Web of Science ®Google Scholar
• LEARISH R, OHASHI T, ROBBINS PA et al.: Retroviral gene transfer and sustained expression of human arylsulfatase A. Gene Ther. (1996) 3(4):343–349.
   PubMed Web of Science ®Google Scholar
• SANGALLI A, TAVEGGIA C, SALVIATI A, WRABETZ L, BORDIGNON C, SEVERINI GM: Transduced fibroblasts and metachromatic leukodystrophy lymphocytes transfer arylsulfatase A to myelinating glia and deficient cells in vitro. Hum. Gene Ther. (1998) 9(14):2111–2119.
   PubMed Web of Science ®Google Scholar
• TSUTSUDAASANO A, MIGITA M, TAKAHASHI K, SHIMADA T: Transduction of fibroblasts and CD34+ progenitors using a selectable retroviral vector containing cDNAs encoding arylsulfatase A and CD24. J. Hum. Genet. (2000) 45(1):18–23.
   PubMed Web of Science ®Google Scholar
• MATZNER U, HABETHA M, GIESELMANN V: Retrovirally expressed human arylsulfatase A corrects the metabolic defect of arylsulfatase A-deficient mouse cells. Gene Ther. (2000) 7:805–812.
   PubMed Web of Science ®Google Scholar
• •Proof that the human ASA can substitute for the murine enzyme and compensate the catabolic defect of ASA-deficient mouse cells.
   Google Scholar
• MATZNER U, HARZER K, LEARISH RD, BARRANGER JA, GIESELMANN V: Long-term expression and transfer of arylsulfatase A into brain of arylsulfatase A-deficient mice transplanted with bone marrow expressing the arylsulfatase A cDNA from a retroviral vector. Gene Ther. (2000) 7(14):1250–1257.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the transfer of extraordinary high levels of ASA into the CNS by BMSC-GT.
   Google Scholar
• MATZNER U, HARTMANN D, LULLMANN-RAUCH R et aL: Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations. Gene Ther. (2002) 9(1):53–63.
   PubMed Web of Science ®Google Scholar
• ••Describes the therapeutic potency ofretrovirally mediated BMSC-GT in a mouse model for MLD.
   Google Scholar
• EMERMAN M, TEMIN HM: Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell (1984) 39(3 Pt 2):449–467.
   Google Scholar
• PESTOVA TV, KOLUPAEVA VG, LOMAKIN TB et al.: Molecular mechanisms of translation initiation in eukaryotes. Proc. Natl. Acad. Sci. USA (2001) 98(13):7029–7036.
   PubMed Web of Science ®Google Scholar
• MUSCHOL N, MATZNER U, TIEDE S, GIESELMANN V, ULLRICH K, BRAULKE T: Secretion of phosphomannosyl-deficient arylsulphatase A and cathepsin D from isolated human macrophages. Biochem. J. (2002) 368(Pt 3):845–853.
   PubMedGoogle Scholar
• •Demonstrates the expression of uptake-incompetent ASA by cultured cells of the monocyte-phagocyte system.
   Google Scholar
• D'AZZO k Gene transfer strategies for correction of lysosomal storage disorders. Acta HaematoL (2003) 110(2–3):71-85.
   Google Scholar
• ••An excellent review summarisingimportant aspects of gene therapy for LSDs.
   Google Scholar
• MATZNER U: Therapy of lysosomal storage diseases. In: Lysosomes. Saftig P (Ed.), Landes Bioscience, Georgetown, TX, USA. (In Press).
   Google Scholar
• ••A review also dealing with possiblealternatives to gene therapy.
   Google Scholar
• DHAMI R, SCHUCHMAN EH: Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy. J. Biol. Chem. (2004) 279(2):1526–1532.
   PubMed Web of Science ®Google Scholar
• •This report demonstrates impaired endocytosis in certain sphingolipidosis cells.
   Google Scholar
• MIRANDA SR, HEX, SIMONARO CM et al.: Infusion of recombinant human acid sphingomyelinase into niemann-pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. (2000) 14:1988–1995.
   PubMed Web of Science ®Google Scholar
• MARTINO S, EMILIANI C, TANCINI B et al.: Absence of metabolic cross-correction in Tay-Sachs cells: implications for gene therapy. J. Biol. Chem. (2002) 277(23):20177–20184.
   PubMed Web of Science ®Google Scholar
• •Demonstrates defective lysosomal targeting in certain sphingolipidosis cells.
   Google Scholar
• KLEIN D, FOGH J, MUSCHOL N, BRAULKE T, GIESELMANN V, MATZNER U: Enzyme substitution in a cell culture and a mouse model for metachromatic leukodystrophy. International Symposium on Lysosomal Disorders - Diseases, Treatment and Pathophysiological Aspects. Fulda, Germany (2003) (scientific paper in preparation).
   Google Scholar
• •The presented data demonstrate normal endocytic routing of ASA in MLD cells leading to cross-correction of the catabolic defect.
   Google Scholar
• MATZNER U, SCHESTAG F, HARTMANN D et al.: Bone marrow stem cell gene therapy of arylsulfatase A-deficient mice, using an arylsulfatase A mutant that is hypersecreted from retrovirally transduced donor-type cells. Hum. Gene Ther. (2001) 12(9):1021–1033.
   PubMed Web of Science ®Google Scholar
• •Indicates that efficient treatment of MLD by gene therapy requires phosphorylated ASA.
   Google Scholar
• VOGLER C, GALVIN N, LEVY B et al.: Transgene produces massive overexpression of human beta-glucuronidase in mice, lysosomal storage of enzyme, and strain-dependent tumors. Proc. Natl. Acad. Sci. USA (2003) 100(5):2669–2673.
   PubMed Web of Science ®Google Scholar
• IOANNOU YA, BISHOP DF, DESNICK RJ: Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion. J. Cell Biol. (1992) 119(5):1137–1350.
   PubMed Web of Science ®Google Scholar
• DIERKS T, SCHMIDT B, BORISSENKO LV et al.: Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell (2003) 113(4):435–444.
   PubMed Web of Science ®Google Scholar
• ANSON DS, MULLER V, BIELICKI J, HARPER GS, HOP WOOD JJ: Overexpression of N-acetylgalactosamine-4-sulphatase induces a multiple sulphatase deficiency in mucopolysaccharidosis-type-VI fibroblasts. Biochem. J. (1993) 294(Pt 3):657–662.
   PubMedGoogle Scholar
• OHASHI T, MATALON R, BARRANGER JA, ETO Y: Overexpression of arylsulfatase A gene in fibroblasts from metachromatic leukodystrophy patients does not induce a new phenotype. Gene Ther. (1995) 2(6):363–368.
   PubMed Web of Science ®Google Scholar